Poseida prices $224M IPO as two other biotechs eye listings of similar size

By pricing its $224 million IPO late Thursday, Poseida became the first of three biotechs slated to trade on NASDAQ for the first time Friday, one of which is also seeking an offering upwards of $200 million.

Poseida Therapeutics Inc. (NASDAQ:PSTX) had upsized its proposed share count ahead of the pricing. Another company likely to price late Thursday, Nkarta Inc., boosted both the number of shares and the price range earlier in the day from a prior proposal...